GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Brain+ AS (OCSE:BRAINP) » Definitions » Capex-to-Revenue

Brain+ AS (OCSE:BRAINP) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brain+ AS Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Brain+ AS's Capital Expenditure for the six months ended in Dec. 2023 was kr-1.20 Mil. Its Revenue for the six months ended in Dec. 2023 was kr0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Brain+ AS Capex-to-Revenue Historical Data

The historical data trend for Brain+ AS's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brain+ AS Capex-to-Revenue Chart

Brain+ AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
- - - - -

Brain+ AS Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Brain+ AS's Capex-to-Revenue

For the Health Information Services subindustry, Brain+ AS's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brain+ AS's Capex-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Brain+ AS's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Brain+ AS's Capex-to-Revenue falls into.



Brain+ AS Capex-to-Revenue Calculation

Brain+ AS's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3.513) / 0
=N/A

Brain+ AS's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.196) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Brain+ AS  (OCSE:BRAINP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Brain+ AS Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Brain+ AS's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Brain+ AS (OCSE:BRAINP) Business Description

Traded in Other Exchanges
N/A
Address
Kobmagergade 53, 3rd Floor, Copenhagen, DNK, DK-1150
Brain+ AS is a digital therapeutics company. It restores patients' quality of life by treating and detecting a cognitive decline in Alzheimer's disease and dementia through digital means. It has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI).

Brain+ AS (OCSE:BRAINP) Headlines

No Headlines